Table 2 Pneumonia and treatment characteristics
Bacteremia + | Bacteremia − | P value | |||
|---|---|---|---|---|---|
N | % | N | % | ||
93 | 12.16 % | 672 | 87.84 % | ||
Pneumonia characteristics | |||||
Pre-pneumonia LOS, days | |||||
Mean [SD] | 11.3 [15.0] | 8.6 [13.7] | |||
Median (IQR) | 4.7 (1.1, 15.8) | 4.6 (0.9, 11) | 0.333 | ||
ICU prior to pneumonia | 15 | 16.13 % | 94 | 13.99 % | 0.634 |
Pneumonia type | |||||
CAP or HCAP | 35 | 37.63 % | 218 | 32.44 % | 0.318 |
HAP or VAP | 58 | 62.37 % | 454 | 67.56 % | |
ICU at onset of pneumonia | 66 | 70.97 % | 485 | 72.17 % | 0.806 |
ICU transfer after pneumonia onset | 5 | 5.38 % | 19 | 2.83 % | 0.198 |
No ICU during pneumonia admission | 7 | 7.53 % | 73 | 10.86 % | 0.372 |
Specimen type | |||||
Bronchial brushing | 0 | 0.00 % | 1 | 0.15 % | 0.565 |
Bronchial washing | 8 | 8.60 % | 33 | 4.91 % | |
Bronchoalveolar lavage | 7 | 7.53 % | 55 | 8.18 % | |
Sputum | 7 | 7.53 % | 73 | 10.86 % | |
Induced sputum | 4 | 4.30 % | 23 | 3.42 % | |
Tracheal aspirate | 67 | 72.04 % | 487 | 72.47 % | |
Illness severity | |||||
Mechanical ventilation | 71 | 76.34 % | 499 | 74.26 % | 0.705 |
Vasopressors | 40 | 43.01 % | 228 | 33.93 % | 0.104 |
APACHE II (at pneumonia onset) | |||||
Mean [SD] | 17.5 [6.0] | 16.1 [6.0] | |||
Median (IQR) | 16 (13, 22) | 16 (12, 20) | 0.045 | ||
Day of pneumonia onset peak WBC | |||||
Mean [SD] | 15.4 [7.2] | 15.3 [12.5] | |||
Median (IQR) | 14.2 (10.5, 21.2) | 13.5 (10, 17.9) | 0.232 | ||
Day of pneumonia onset peak temperature, C | |||||
Mean [SD] | 38.1 [1.1] | 38.1 [1.0] | |||
Median (IQR) | 38.2 (37.5, 38.9) | 38.2 (37.3, 38.8) | 0.834 | ||
CrCl (at pneumonia onset) | |||||
Mean [SD] | 50.78 ± 31.42 | 58.84 ± 32.44 | 0.019 | ||
Median (IQR) | 48 (26, 67) | 56 (33, 79) | |||
CrCl > 50 (at pneumonia onset) | 43 | 46.24 % | 379 | 56.40 % | 0.065 |
Treatment characteristics | |||||
Time to first drug, hrs | |||||
Mean [SD] | 8.7 [21.7] | 17.6 [41.7] | |||
Median (IQR) | 0.1 (0.1, 4.0) | 0.1 (0.1, 18.6) | 0.007 | ||
Drug | |||||
Ceftaroline | 6 | 6.45 % | 12 | 1.79 % | 0.015 |
Daptomycin | 13 | 13.98 % | 13 | 1.93 % | <0.001 |
Linezolid | 47 | 50.54 % | 219 | 32.59 % | 0.001 |
Vancomycin | 83 | 89.25 % | 559 | 83.18 % | 0.174 |
Time to drug, hrs | |||||
Ceftaroline | |||||
Mean [SD] | 582.7 [562.5] | 382.1 [653.6] | |||
Median (IQR) | 448.9 (69.6, 1,180.5) | 150.2 (16.6, 440.5) | 0.426 | ||
Daptomycin | |||||
Mean [SD] | 172.7 [252.0] | 648.7 [874.6] | |||
Median (IQR) | 54.3 (0.1, 187.7) | 430.4 (236.7, 580) | 0.017 | ||
Linezolid | |||||
Mean [SD] | 117.3 [171.9] | 138.9 [225.8] | |||
Median (IQR) | 46.5 (12.2, 157.7) | 67.3 (23.0, 170.8) | 0.280 | ||
Vancomycin | |||||
Mean [SD] | 0.9 [0.3] | 0.8 [0.4] | |||
Median (IQR) | 1 (1, 1) | 1 (1, 1) | 0.110 | ||
Number of anti-MRSA drugs used | |||||
0 | 5 | 5.38 % | 85 | 12.65 % | <0.001 |
1 | 36 | 38.71 % | 386 | 57.44 % | |
2 | 43 | 46.24 % | 187 | 27.83 % | |
3 | 9 | 9.68 % | 13 | 1.93 % | |
4 | 0 | 0.00 % | 1 | 15.00 % | |